List view / Grid view
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
This article highlights five of the latest findings that could be used in the development or design of new therapies to treat Parkinson’s disease.
The process of Salmonella typhi to damage DNA has been revealed by researchers at the University of Sheffield which could inform treatments.
An animal model to test HIV infection in infants could lead to biomarkers that predict viral rebound after ART interruption.
New gene mutation discovery could lead to more rapid and effective therapies for tuberculosis.
The novel method for imaging molecules in cells and tissue samples, called DNA microscopy, could improve knowledge of disease development.
A research team has found that blocking a particular kinase in a mouse model of arrhythmogenic cardiomyopathy led to improved survival rates.
A protein that causes pancreatic ductal adenocarcinoma has been identified as a therapeutic target by researchers.
Researchers have mapped a previously uncharted region of the human genome which could lead to tests for certain conditions in the future.
New research is the first to link maladaptive changes in calcium transport by mitochondria to the progression of Alzheimer's disease.
A team from MIT sequenced bacteria samples from the digestive system which can be accessed by researchers to use in the development of treatments.
Researchers have found a new way to treat the inflammation involved in chronic diseases.
Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life after treatment.
Researchers have discovered that a rare muscle disease causes resistance to HIV-1 infection in patients, providing insight into potential therapies.
A protein discovery could lead to a new and highly potent immune-therapeutic drug for the eradication of cancers using natural killer cells.
